(1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid hydrate
| Title | Journal |
|---|---|
| Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601 |
| [New approved drugs for osteoporosis in Japan]. | Clinical calcium 20120601 |
| Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. | Toxicology and applied pharmacology 20120315 |
| Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20111201 |
| Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors. | European journal of medicinal chemistry 20111001 |
| A serendipitous phosphonocarboxylate complex of boron: when vessel becomes reagent. | Chemical communications (Cambridge, England) 20110614 |
| [Minodronic acid- its clinical efficacy and prospects for once-a-month dosing regimen]. | Clinical calcium 20110101 |
| Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway. | Clinical & experimental metastasis 20101001 |
| Minodronate for the treatment of osteoporosis. | Drugs of today (Barcelona, Spain : 1998) 20100101 |
| [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090901 |
| Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090801 |
| A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. | Bone 20090601 |
| [Drugs under development for osteoporosis ]. | Nihon rinsho. Japanese journal of clinical medicine 20090501 |
| [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis]. | Clinical calcium 20090101 |
| [New development in bisphosphonate treatment. Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis]. | Clinical calcium 20090101 |
| New bisphosphonates and trends in drug therapy for osteoporosis: preface. | Clinical calcium 20090101 |
| Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. | Bone 20081101 |
| Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. | Bone 20081101 |
| Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models. | European journal of pharmacology 20080728 |
| Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. | Cancer chemotherapy and pharmacology 20080601 |
| Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies. | Bioorganic & medicinal chemistry letters 20080501 |
| Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. | Cancer science 20080101 |
| [New bone density conservation agents for osteoporosis under research and development: Minodronic acid]. | Nihon rinsho. Japanese journal of clinical medicine 20071128 |
| Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. | Cancer letters 20070808 |
| [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate]. | Clinical calcium 20070101 |
| Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. | BMC cancer 20070101 |
| Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis. | Modern rheumatology 20070101 |
| A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. | British journal of cancer 20061120 |
| Minodronate suppresses prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20060301 |
| Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. | Medical hypotheses 20060101 |
| Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050915 |
| Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. | Biochemical and biophysical research communications 20050304 |
| A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050115 |
| [Minodronic acid hydrate as a new therapeutic agent for osteoporosis]. | Clinical calcium 20050101 |
| Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. | International journal of tissue reactions 20050101 |
| Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. | The American journal of pathology 20041201 |
| Effects of YM529, a novel minodronic acid, on adjuvant arthritis in rats. | Clinical and experimental rheumatology 20040101 |
| Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031101 |
| A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. | Life sciences 20031010 |
| Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. | Cellular signalling 20030701 |
| Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis. | Arthritis and rheumatism 20030601 |
| A new stressed test to predict the foreign matter formation of minodronic acid in solution. | International journal of pharmaceutics 20030130 |
| Failure of stability prediction for minodronic acid injectable by accelerated stability testing. | International journal of pharmaceutics 20020708 |
| Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells. | International journal of hematology 20020601 |
| Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy. | The Journal of endocrinology 20011101 |
| Stabilization of minodronic acid in aqueous solution for parenteral formulation. | International journal of pharmaceutics 20010703 |
| A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. | Leukemia research 20010101 |